Daily longitudinal self-monitoring of mood variability in bipolar disorder and borderline personality disorder  by Tsanas, A. et al.
Journal of Affective Disorders 205 (2016) 225–233Contents lists available at ScienceDirectJournal of Affective Disordershttp://d
0165-03
n Corr
Departm
search B
E-m
tsanasthjournal homepage: www.elsevier.com/locate/jadResearch paperDaily longitudinal self-monitoring of mood variability in bipolar
disorder and borderline personality disorder
A. Tsanas a,b,c,n, K.E.A. Saunders d, A.C. Bilderbeck d, N. Palmius a, M. Osipov a, G.D. Clifford e,f,
G.Μ. Goodwin d, M. De Vos a,c
a Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, UK
b Oxford Centre for Industrial and Applied Mathematics, Mathematical Institute, University of Oxford, UK
c Sleep and Circadian Neuroscience Institute, Nufﬁeld Department of Clinical Neurosciences, UK
d Department of Psychiatry, University of Oxford, UK
e Department of Biomedical Informatics, Emory University, Atlanta, GA, USA
f Department of Biomedical Engineering, Georgia Institute of Technology, USAa r t i c l e i n f o
Article history:
Received 10 May 2016
Received in revised form
21 June 2016
Accepted 26 June 2016
Available online 2 July 2016
Keywords:
Bipolar disorder
Borderline personality disorder
Digital health
Mood assessment
Mood monitoring
Patient reported outcome measuresx.doi.org/10.1016/j.jad.2016.06.065
27/& 2016 The Authors. Published by Elsevie
esponding author. Present address: Institute
ent of Engineering Science, University of O
uilding, Headington, Oxford OX3 7DQ, UK.
ail addresses: athanasios.tsanas@eng.ox.ac.uk,
anasis@gmail.com (A. Tsanas).a b s t r a c t
Background: Traditionally, assessment of psychiatric symptoms has been relying on their retrospective
report to a trained interviewer. The emergence of smartphones facilitates passive sensor-based mon-
itoring and active real-time monitoring through time-stamped prompts; however there are few validated
self-report measures designed for this purpose.
Methods: We introduce a novel, compact questionnaire, Mood Zoom (MZ), embedded in a customised
smart-phone application. MZ asks participants to rate anxiety, elation, sadness, anger, irritability and
energy on a 7-point Likert scale. For comparison, we used four standard clinical questionnaires ad-
ministered to participants weekly to quantify mania (ASRM), depression (QIDS), anxiety (GAD-7), and
quality of life (EQ-5D). We monitored 48 Bipolar Disorder (BD), 31 Borderline Personality Disorders (BPD)
and 51 Healthy control (HC) participants to study longitudinal (median7 iqr: 3137194 days) variation
and differences of mood traits by exploring the data using diverse time-series tools.
Results: MZ correlated well ( )> <pR 0. 5, 0.0001 with QIDS, GAD-7, and EQ-5D. We found statistically
strong ( )> <pR 0. 3, 0.0001 differences in variability in all questionnaires for the three cohorts. Com-
pared to HC, BD and BPD participants exhibit different trends and variability, and on average had higher
self-reported scores in mania, depression, and anxiety, and lower quality of life. In particular, analysis of
MZ variability can differentiate BD and BPD which was not hitherto possible using the weekly ques-
tionnaires.
Limitations: All reported scores rely on self-assessment; there is a lack of ongoing clinical assessment by
experts to validate the ﬁndings.
Conclusions: MZ could be used for efﬁcient, long-term, effective daily monitoring of mood instability in
clinical psychiatric practice.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The potential beneﬁts of reliable monitoring of symptom se-
verity is acknowledged in many chronic conditions (Steventon
et al., 2012; Tsanas, 2012), but particularly for mental health
(American Psychiatric Association, 2013; Holmes et al., 2016; La-
nata et al., 2015; Solomon et al., 2010). Residual symptoms arer B.V. This is an open access article
of Biomedical Engineering,
xford, Old Road Campus Re-
tsanas@maths.ox.ac.uk,important in psychiatric disorders because they directly impair
social and economic activity and increase the risk of new episodes.
Capture and monitoring of symptom variability and progression
prospectively (Slade, 2002; Solomon et al., 2010) is accordingly
widely encouraged in treatment guidelines.
Monitoring of mood states is often used in the assessment and
management of mood disorders. Traditionally, self-monitoring of
mood using Patient Reported Outcome Measures (PROMs) was
achieved using paper-based and more recently computer-based
questionnaires (Bopp, 2010, Malik, 2012) but in recent years the
ubiquity of mobile networks and the rapid evolution of smart-
phone technology have led to an increasing focus on the use of
mobile applications (Faurholt-Jepsen et al., 2015; Schärer et al.,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Summary of the AMoSS study details for the three groups.
Bipolar Dis-
orders (BD)
Borderline Person-
ality Disorders
(BPD)
Healthy Con-
trols (HC)
Originally recruited 53 33 53
Processed data from 48 31 51
Days in study 3537261 3137107 2767253
Age (years) 38721 34715 37720
Gender (males) 16 2 18
Any psychotropic
medication
47 23 0
Lithium 19 0 0
Anticonvulsant 19 1 0
Antipsychotic 33 6 0
Antidepressants 17 23 0
A. Tsanas et al. / Journal of Affective Disorders 205 (2016) 225–2332262015; Schwartz et al., 2016). This approach has advantages because
mood states can be reported in real time without the incon-
venience of logging to a computer and thus self-ratings should be
less prone to recall bias (Proudfoot et al., 2010). However, the
optimal temporal frequency of mood monitoring remains the
source of some uncertainty (Moore et al., 2014). Here, we describe
the validation of a smartphone-based application for the delivery
of daily mood monitoring in two patient groups where mood in-
stability is a common. Bipolar Disorder (BD) and Borderline Per-
sonality Disorder (BPD) affect around 2% of the population re-
spectively. Traditional descriptions of BD comprising clear epi-
sodes of elated or depressed mood interspersed with periods of
euthymia mask the true course of the disorder which is char-
acterised by chronic mood instability and poor inter-episode
function. The duration of these periods may vary considerably
from weeks to months, with depression typically dominating the
longitudinal course of the disorder (Anderson et al., 2012). Bor-
derline personality disorder is a pervasive disorder where mood
instability is accompanied by impulsivity, interpersonal dysfunc-
tion, repeated suicidal gestures, an uncertain sense of self, in-
appropriate anger and a fear of abandonment. Mood instability in
BPD is thought to differ from other disorders in its nature (Koe-
nigsberg et al., 2002) and relate to an inability to modulate emo-
tional responses (Gratz et al., 2006; Linehan, 1993) although few
direct comparisons with BD have been made. BD and BPD can be
clearly distinguished using laboratory measures of social co-
operation and reward learning (Saunders et al., 2015) but in clin-
ical practice their distinction can be far more challenging. Correct
diagnosis is essential given their divergent treatment approaches;
BD requires a long term medication (Goodwin et al., 2016)
whereas there are no licensed medications for BPD and psycho-
logical interventions are recommended (NICE, 2009). We stress
that this study focuses on mood variability and not emotional
dysregulation. The latter refers to short-term (from seconds to a
few hours) behavioural outbursts, and is the result of poor reg-
ulation of emotional responses. Mood is less speciﬁc than emo-
tions and refers to an internal psychological state which can last
from hours to months; mood variability aims to characterize long-
term mood disturbances.
The aims of the study were to: (a) introduce and validate a
novel clinical questionnaire used for daily mood monitoring as
part of a smartphone application, (b) explore the longitudinal
variation in mood characteristics of BD, BPD, and Healthy Control
(HC) participants extracted from this new questionnaire as com-
pared to four established psychiatric questionnaires quantifying
mood on a weekly basis and (c) to test the hypothesis that mood
variability might discriminate BD and BPD groups from HC and
more critically from each other. We present results from a rela-
tively large number of participants in the context of longitudinal
mood monitoring, tracking their mood variation for multiple
months, as opposed to other studies that were conﬁned to a few
weeks (e.g. Holmes et al., 2016; Schwartz et al., 2016), and using
multiple questionnaires (most previous studies focus on a single
questionnaire to investigate symptom variation, e.g. depression,
for example Bonsall et al., 2012; Moore et al., 2014; Bonsall et al.,
2015; Holmes et al., 2016). Moreover, most other studies focus
solely on a single disorder (e.g. BD, Bonsall et al., 2015; Faurholt-
Jepsen et al., 2015; Holmes et al., 2016; Lanata et al., 2015),
whereas we have also recruited people diagnosed with BPD, and
compared ﬁndings against HC.Hypnotics 3 2 0
Of the 139 recruited participants, nine participants were excluded from further
analysis who withdrew consent or failed to provide at least two months of data.
The details provided refer to the 130 participants whose data was further pro-
cessed. Where appropriate, we summarised the distributions in the form media-
n7 iqr range.2. Data
The data were collected as part of the Automated Monitoring of
Symptom Severity (AMoSS) study exploring mood, activity andphysiological variables (Palmius et al., 2014). The study was ob-
servational, and independent from the clinical care the partici-
pants received. We recruited 139 participants: 53 diagnosed with
BD, 33 diagnosed with BPD and 53 age-matched HC. BD and HC
were also gender-matched; the BPD group were predominantly
female. The participants were recruited for an initial three-month
study period, with an option to remain in the study for 12 months
or longer. We excluded data from participants who either with-
drew consent (one participant), or completed participation with-
out providing at least two months of data. We processed data from
130 participants, 120 of whom had provided data for at least three
months, and 61 participants provided data for at least 12 months.
All participants gave written informed consent to participate in
the study. All patient participants were screened by an experi-
enced psychiatrist (KEAS) using the Structured Clinical Interview
for DSM IV and the borderline items of the International Person-
ality Disorder Examination (IPDE) (Loranger et al., 1994). The study
was approved by the NRES Committee East of England – Norfolk
(13/EE/0288) and the Research and Development department of
Oxford Health NHS Foundation Trust. The demographic details of
the participants are summarised in Table 1.
We used the Wilcoxon statistical hypothesis test to assess
whether there are statistically signiﬁcant differences conducting
pairwise comparisons between the three cohorts. We found no
statistically signiﬁcant differences ( >p 0.01) when comparing the
days into the study, and the ages of the participants for the three
cohorts. Similarly, there was no statistically signiﬁcant difference
in terms of gender between HC and BD, but gender was statisti-
cally signiﬁcantly different between HC and BPD ( =p 0.003), and
also between BD and BPD ( = )p 0.006 .
2.1. Established questionnaires
The participants completed the following standardized ques-
tionnaires on a weekly basis using the True Colours (TC) system
(www.truecolours.nhs.uk) online: (i) Altman Self-rating Mania
scale (ASRM) (Altman et al., 1997) to assess mania, (ii) Quick In-
ventory of Depressive Symptomatology Self-Report (QIDS) (Rush
et al., 2003) to assess depression, (iii) Generalised Anxiety Dis-
order (GAD-7) (Spitzer et al., 2006) to assess anxiety, and (iv) EQ-
5D (EuroQoL) assessing quality of life.
ASRM is a ﬁve-item scale requesting participants to report on
(1) mood, (2) self-conﬁdence, (3) sleep disturbance, (4) speech,
and (5) activity level over the past week. Items are scored on a 0
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scores ranging from 0 to 20. Miller et al. (2009) proposed a cut-off
score of 5.5 assess a manic episode on the basis that this threshold
demonstrated an optimal trade-off between sensitivity and
speciﬁcity.
QIDS is comprised of 16 items, which constitute nine symptom
domains for depression. Each domain contributes 0–3 points, with
total scores ranging from 0 to 27. The suggested clinical ranges are
5 or less denoting normal, 6–10 denoting mild depression, 11–15
denoting moderate depression, 16–20 denoting severe depression,
and 21–27 denoting very severe depression.
GAD-7 contains seven items each of which is scored from 0
(symptom-free) to 3 (nearly every day), with total scores ranging
from 0 to 21. Kroenke et al. (2007) endorsed using the threshold
cut-offs at 5, 10, and 15 to denote mild, moderate, and severe
anxiety, respectively.
EQ-5D is a standardised validated questionnaire assessing
mental health status, and was developed by the EuroQol Group in
order to provide a simple, generic measure of health for clinical
and expedient evaluation. Only the item where participants
quantify their quality of life (0–100%) was used.
2.2. The daily questionnaire: Mood Zoom (MZ)
MZ was conceived to identify predominant mood states, based
on simple questions that can be easily answered on the smart-
phone's screen. It is comprised of the following six descriptor
items: (1) anxious, (2) elated, (3) sad, (4) angry, (5) irritable, and
(6) energetic. Participants were asked to assess the extent that
each descriptor captured their mood, and to rate this on a Likert
scale (1–7). The six items were based on experience sampling
methodology. Participants were prompted to report their mood
during the study daily in the evening at a pre-speciﬁed time
convenient for each participant. The MZ questionnaire was im-
plemented as part of a customised Android application developed
for this study (a screenshot appears in Fig. 1).Fig. 1. Mood Zoom questionnaire as it typically appears on a participant's phone.3. Methods
This section summarises the main methodological attempts to
understand the data.
3.1. Adherence
Adherence was deﬁned as the proportion of prompted re-
sponses that were completed. For MZ it required that participants
completed their daily assessment within the day of the prompt on
their smartphone. For the weekly questionnaires, it required the
completion of the weekly questionnaire within two days before or
after the day on which we requested it be completed. In total, we
processed 39,114 samples for MZ, and 7709 samples for the es-
tablished weekly questionnaires.
In the Supplementary material we explore whether there is any
structure in the missing entries.
3.2. Finding the internal structure of the new MZ questionnaire
Multidimensional data can often be described in terms of latent
variable structure, for example Principal Component Analysis
(PCA). Although recent research focuses on more complicated
methods, PCA has the advantage that it is considerably more in-
terpretable as a linear projection method, and also leads to a un-
ique solution without additional ﬁne-tuning of any hyper-para-
meters. It had been used previously to understand the internal
structure of QIDS (Rush et al., 2006).3.3. Associating MZ with the established psychiatric questionnaires
In order to validate the MZ questionnaire, we computed its
statistical association against established self-report ques-
tionnaires. We used Spearman correlation coefﬁcients to quantify
the associations of each questionnaire domain for the QIDS, ASRM,
GAD-7 and EQ-5D. We adopted the standard guideline in medical
applications that statistical correlations with a magnitude equal or
larger than 0.3 are statistically strong (Meyer et al., 2001; Hemphill,
2003; Tsanas et al., 2013).
The established questionnaires capture experience over the
preceding week, whereas MZ is recorded on a daily basis. To allow
a fair comparison we averaged the daily MZ item values over the
week before the weekly ratings were made. We explored alter-
native approaches for summarizing the seven MZ entries and
present the results in the Supplementary material.
3.4. Quantifying variability
Our hypothesis was that variability might discriminate BD and
BPD groups from HC and more critically from each other. To
A. Tsanas et al. / Journal of Affective Disorders 205 (2016) 225–233228quantify the variability of our time-series, we used the standard
deviation and the Teager-Kaiser Energy Operator (TKEO), entropy,
and the Root Mean Squared Successive Differences (RMSSD) for
each of the six MZ items, and for each of the items of the other
questionnaires. RMSSD is a fairly simple algorithmic approach to
quantify variability and was recently used in a related application
(Gershon and Eidelman, 2014). The TKEO has been widely used in
other medical applications to identify patterns successfully (De
Vos et al., 2011; Solnik et al., 2010; Tsanas, 2012). It is an appli-
cation of an operator resulting in a vector output; we used the
mean TKEO value to summarise its content as a scalar.
Speciﬁcally, we computed:
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where N is the total number of samples for the investigated
variable, and xi indicates a realisation of the investigated variable
(e.g. QIDS or MZ).
3.5. Differentiating groups on the basis of TC and MZ
The questionnaires can be thought of as multivariate signals,
sampled across a range of items (ﬁve items for ASRM, sixteen for
QIDS, seven for GAD-7, one for EQ-5D, six for MZ). Here, we stu-
died both the items independently, and also used the total score
for each week. We studied the MZ items independently, and also
using the three principal components which resulted from the
application of PCA.
We computed pairwise comparisons between the three groups
using the Wilcoxon rank sum statistical hypothesis test. The null
hypothesis is that the samples from the two groups under in-
vestigation come from distributions with equal medians.Fig. 2. Longitudinal adherence as a function of the time into the study for each of t
questionnaires is almost identical to ASRM. We remark that participant adherence was m
after approximately a year. The participants were originally recruited for an initial three-
this might explain the increase in % variability beyond the ﬁrst three months. However
satisfactory.4. Results
4.1. Participant adherence for the weekly questionnaires and for the
daily MZ questionnaire
The participant adherence throughout the study was
(median7 iqr%) 81.2729.2 for MZ, and 86.3749.8 for the weekly
questionnaires. Furthermore, we tested whether participants gra-
dually grew tired of completing the daily and weekly ques-
tionnaires. Fig. 2 presents the response rates for MZ and weekly
questionnaires. Overall, these plots indicate that the overall par-
ticipant adherence remained relatively stable in the study, parti-
cularly for HC and BD. Most participants completed participation
in the study after one year, but some participants have provided
data for considerably longer and tend to be very compliant. In
order not to bias the results, we only present ﬁndings for up to one
year. The adherence variability progressively increased, particu-
larly after the third month into the study; this might reﬂect that
participants were originally recruited for an initial three-month
study period. Speciﬁcally, after the ﬁrst three months MZ ad-
herence was BD: 86.7723.3, BPD: 92.8715.6, HC: 92.2717.2, and
weekly questionnaire adherence was BD: 92.3720.2, BPD:
100.0715.2, HC: 100.0076.58, whilst after 12 months the MZ
adherence was BD: 81.9716.7, BPD: 79.2724.4, HC: 82.9728.3,
and weekly questionnaire adherence was BD: 86.3749.0, BPD:
65.7737.3, HC: 93.14737.3.
4.2. Latent variable structure of the MZ questionnaire
The PCA results are summarised in Table 2, and using the ﬁrst
three components we can explain 85% of the variance in MZ.
Moreover, the components have tentative interpretations, sum-
marizing “negative”, “positive” and “irritability” affects in MZ.
Henceforth, we denote these components as “negative MZ”
(MZneg), “positive MZ” (MZpos) and “irritability MZ” (MZirr), re-
spectively. Note that “irritability MZ” is dominated by the corre-
sponding “irritable” and “angry” items in MZ, whilst being inversely
associated with anxiety and sadness. Tables S1, S2, and S3 in the
Supplementary material provide the results for the latent variable
structure of MZ for each of the three groups separately; the po-
sitive and negative MZ dimensions (P1 and P2) were the same
within groups (i.e. they were stable across the three cohorts)
whereas P3 was less stable (the third MZ component was different
for each of the three cohorts). We veriﬁed the stability of the PCAhe three groups for (a) MZ and (b) ASRM. The adherence for the other weekly
ore variable as a function of days into study, but remained very high overall even
month study period, with an option to remain in the study for 12 months or longer;
, we consider the approximately 80% adherence even at the end of the study very
Table 2
Principal components to identify the latent variable structure of Mood Zoom.
P1 P2 P3 P4 P5 P6
Anxious 0.55 0.08 0.47 0.27 0.60 0.18
Elated 0.11 0.76 0.11 0.53 0.33 0.01
Sad 0.52 0.04 0.43 0.39 0.57 0.25
Angry 0.42 0.11 0.46 0.11 0.21 0.74
Irritable 0.47 0.12 0.60 0.15 0.14 0.60
Energetic 0.13 0.62 0.02 0.67 0.38 0.03
% Total variance explained 55 77 85 91 97 100
Tentative interpretation “Negative feelings” “Positive feelings” “Irritability”
Bold entries indicate the loadings which dominate each principal component.
Table 3
Statistical associations (Spearman correlation coefﬁcient) between MZ and the constituent items and total scores of the established weekly questionnaires (ASRM, QIDS,
GAD-7, EQ-5D).
MZ items MZ factors
Anxious Elated Sad Angry Irritable Energetic Negative Positive Irritability
ASRM Happy 0.08 0.26 0.07 0.07 0.11 0.19 0.06 0.26 0.06
Conﬁdent 0.09 0.26 0.05 0.08 0.12 0.19 0.06 0.26 0.04
Sleep 0.18 0.16 0.15 0.18 0.24 0.08 0.18 0.17 0.01
Talkative 0.16 0.21 0.14 0.15 0.20 0.11 0.16 0.21 0.06
Active 0.14 0.21 0.12 0.13 0.15 0.19 0.12 0.24 0.06
QIDS Sleep 0.38 0.08 0.33 0.31 0.34 0.13 0.39 0 0.02
Sad 0.65 0.01 0.76 0.55 0.53 0.16 0.71 0.08 0.30
Appetite/weight 0.46 0.02 0.39 0.35 0.39 0.17 0.46 0.02 0.09
Concentration 0.59 0.09 0.56 0.46 0.49 0.23 0.61 0.02 0.18
Self-view 0.59 0.03 0.63 0.45 0.46 0.18 0.62 0.04 0.25
Suicide 0.47 0.06 0.56 0.41 0.39 0.17 0.53 0.01 0.16
Interest 0.52 0.07 0.57 0.41 0.43 0.20 0.56 0 0.18
Energy 0.54 0.12 0.55 0.39 0.42 0.27 0.57 0.06 0.21
Restless 0.57 0.04 0.55 0.44 0.49 0.15 0.60 0.05 0.15
GAD-7 Nervous/anxious 0.72 0 0.64 0.53 0.55 0.16 0.69 0.08 0.25
Control worries 0.67 0 0.66 0.54 0.53 0.14 0.67 0.1 0.24
Worried 0.69 0.01 0.66 0.54 0.54 0.13 0.67 0.11 0.25
Relaxed 0.68 0.02 0.62 0.51 0.55 0.15 0.67 0.08 0.22
Restless 0.54 0.09 0.50 0.44 0.45 0.04 0.54 0.16 0.15
Irritable 0.63 0.07 0.58 0.61 0.69 0.12 0.67 0.16 0
Afraid 0.67 0.04 0.67 0.54 0.54 0.17 0.68 0.07 0.2
EQ-5D 0.58 0.15 0.55 0.46 0.50 0.37 0.63 0.11 0.09
Total ASRM 0.19 0.26 0.16 0.17 0.22 0.17 0.17 0.27 0.07
QIDS 0.67 0.05 0.69 0.53 0.56 0.22 0.71 0.03 0.23
GAD-7 0.77 0.03 0.72 0.61 0.65 0.15 0.77 0.13 0.23
Bold entries indicate statistically strong associations (Spearman ≥R 0.3). All entries with ≥R 0.1 were statistically signiﬁcant ( <p 0.0001). We used the nine QIDS domains
rather than the 16 items, because depression is clinically assessed in this way. Each of the items of the weekly questionnaires is presented as a sentence to participants; we
present these as words here to facilitate comparisons. The MZ factors were determined using the PCA loadings computed in Table 2.
Table 4
Summary statistics of the questionnaires used in the study, and statistical signiﬁcance pairwise comparisons across the three groups (BD, BPD, HC) using the Wilcoxon
statistical hypothesis test.
BD (median7 iqr) BPD (median7 iqr) HC (median7 iqr) BD vs BPD (p-value) BD vs HC (p-value) BPD vs HC (p-value)
Total ASRM 1.0073.00 1.0072.00 0.0071.00 0.8128 0.0008 0.0023
QIDS 6.2576.75 14.5075.88 1.0072.25 6.0194e08 2.9603e12 1.1331e13
GAD-7 5.0076.00 12.0079.00 0.0071.00 1.1245e05 1.1962e10 2.8181e14
EQ-5D 68.00718.75 60.00721.50 85.00716.00 0.0225 2.6322e08 4.6093e11
MZ MZneg 3.5872.31 6.4473.27 1.7371.39 5.4323e05 3.4962e06 4.1247e11
MZpos 4.0571.92 4.8572.26 4.2072.67 0.2608 0.9163 0.3973
MZirr 0.1670.71 0.4771.41 0.0070.42 0.0116 0.2949 0.0032
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Table 5
Comparing variability during the low monitoring period across the three groups, and statistical signiﬁcance pairwise comparisons across the three groups (BD, BPD, HC)
using the Wilcoxon statistical hypothesis test.
BD (median7 iqr) BPD (median7 iqr) HC (median7 iqr) BD vs BPD (p-value) BD vs HC (p-value) BPD vs HC (p-value)
ASRMstd 2.4071.99 2.0371.55 0.8771.36 0.7291 1.0506e07 1.7383e06
ASRMTKEO 2.7376.46 3.8777.34 0.7872.09 0.4646 8.4909e05 3.6978e06
ASRMRMSSD 2.4771.00 2.3270.48 1.8470.82 0.4424 1.1898e05 0.0001
ASRMentropy 1.8171.26 2.3371.71 0.9171.43 0.3204 8.4268e07 3.8933e07
QIDSstd 3.3972.29 3.5471.67 1.1570.91 0.1834 2.7408e10 3.5538e11
QIDSTKEO 10.45716.87 18.64721.05 1.1473.57 0.0080 7.1641e07 5.6639e10
QIDSRMSSD 2.8372.06 3.6371.63 1.3770.93 0.0161 5.1287e08 3.8656e10
QIDSentropy 2.6170.73 2.8170.60 1.9470.64 0.0400 7.4278e07 6.7001e09
GAD-7std 3.1772.06 2.8671.47 0.8870.96 0.2701 4.7697e12 7.6226e09
GAD-7TKEO 7.71711.88 12.45714.75 0.8572.77 0.2667 7.4507e09 2.1025e07
GAD-7RMSSD 2.7371.61 3.1171.22 1.0370.96 0.9292 1.0668e10 3.8804e08
GAD-7entropy 2.6670.68 2.5370.46 1.7670.85 0.1089 2.3571e10 4.9003e07
EQ5Dstd 9.4879.70 11.7477.60 5.0474.42 0.2746 1.7334e06 6.9127e08
EQ5DTKEO 290.177425.40 283.137329.10 388.047554.98 0.6457 0.0357 0.008
EQ5DRMSSD 8.5579.97 11.7879.25 5.4074.53 0.0282 5.3213e05 3.7823e08
EQ5Dentropy 3.6870.76 3.9170.63 3.2070.83 0.1206 7.4667e05 3.2071e06
MZnegstd 1.8371.02 2.1370.94 0.8070.92 0.0166 3.8065e08 1.9054e11
MZnegTKEO 2.0272.03 4.0472.86 0.4770.97 0.0002 1.4284e07 2.0344e11
MZnegRMSSD 1.7770.86 2.3770.69 0.8670.89 0.0001 6.0851e07 1.5645e11
MZnegentropy 1.9470.66 2.2170.40 1.1671.25 0.0040 1.6629e07 3.2102e11
MZposstd 1.3370.55 1.5370.73 0.8870.49 0.0747 0.0002 1.2968e05
MZposTKEO 1.2571.24 1.8271.93 0.7370.96 0.0329 0.0055 6.6719e05
MZposRMSSD 1.3870.69 1.6970.85 0.8970.56 0.0041 0.0015 2.3122e06
MZposentropy 1.7370.47 1.8470.54 1.4170.61 0.0451 0.0227 0.00051794
MZirrstd 0.9870.36 1.1970.41 0.4870.46 4.6748e05 8.6713e08 5.0433e11
MZirrTKEO 0.6670.57 1.0971.02 0.2070.36 7.7156e06 6.5418e07 1.5792e10
MZirrRMSSD 1.0970.46 1.3970.57 0.6170.54 1.2282e05 6.3094e07 2.1572e10
MZirrentropy 1.3570.46 1.6070.37 0.8671.12 0.0001 1.9641e05 1.3647e08
Statistically signiﬁcant differences at the p¼0.05 level appear in bold. “MZneg” denotes the negative factor of MZ, “MZpos” denotes the positive factor of MZ, and “MZirr” the
irritability factor of MZ computed using the PCA loadings (see Table 2).
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vestigation of the latent variable structure stability” of the Sup-
plementary material.
4.3. Associating MZ with TC questionnaires
Table 3 summarises the statistical associations between the MZ
items and the four established questionnaires. There are some
statistically strong correlations between negative MZ items (and
P1) and both items and total scores of QIDS and GAD-7, and EQ5-D.
The signs of the correlations are as would be expected. Positive MZ
items and P2 correlated weakly (o0.3) with ASRM items and not
with other measures. P3 (‘irritability’) did not correlate well with
other measures.
4.4. Summary statistics for the questionnaires and differences be-
tween groups
Table 4 presents summary statistics of the scores on ques-
tionnaires for the three groups for the duration of the trial. For
each participant, we computed the median score for each variable,
before summarizing the entries for each of the three groups.
Median scores for the BD group were higher than HC for ASRM,
QIDS, GAD-7 and MZneg (and lower for EQ-5D). Median scores for
the BPD group were higher than HC for ASRM, QIDS, GAD-7 and
MZneg (and lower for MZirr). Median scores for BPD were higher
than BD for QIDS, GAD-7, MZneg and lower for MZirr and EQ-5D.
4.5. Variability of PROMs
Table 5 summarises the four measures of variability for the
ASRM, QIDS and GAD-7 across the questionnaires during the
weekly monitoring. Overall, there was much greater variation on
all measures for the clinical groups compared to HC. There is someevidence for slightly greater QIDS variability in the BPD group
compared to the BD group, but much greater variability in the
daily measures MZneg, MZpos, MZirr in the BPD group versus BD.5. Discussion
Adherence to both modalities of self-report was high (480%)
for the full observation period of 1 year. Daily MZ items of negative
mood correlated highly with the scores from individual questions
or total weekly scores on the QIDS and GAD-7 questionnaires.
Correlations were weaker between the daily ratings of positive
mood and weekly ASRM scores. Both the clinical groups (BD, BPD)
exhibited greatly increased amplitudes and variability in all self-
reported scores (daily and weekly) compared to HC. For weekly
scores, some measures of the variability of the QIDS suggested a
moderately increased effect in BPD compared to BD. For all daily
scores, the BPD group showed higher variability than BD; the
biggest effect was seen for variation in daily scores of irritability.
Differences in variability tended to be more marked with the TKEO
or RMSSD.
Our experience conﬁrms that the intuitively appealing smart-
phone-based MZ questionnaire is a viable approach to be used in
practice for longitudinal daily monitoring. This is in agreement
with Holmes et al. (2016) who also reported that their BD cohort
was very compliant in daily mood monitoring both pre- and post-
treatment, although their monitoring period only lasted one
month. Similarly, Schwartz et al. (2016) reported very good ad-
herence to daily monitoring for the two-week duration of their
trial. To our knowledge, this is the ﬁrst time that longitudinal daily
mood monitoring has been reported from such a large number of
participants tracked formany months, as opposed to a few weeks. It
was a community study and participants were engaging in their
normal activities rather than being monitored under carefully
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have not previously been studied in the same way. In addition to
PROMs, there is an increasing body of research literature on
studying mental disorders using objective behavioural and phy-
siological signals to develop reliable biomarkers. The utility of
smart phones to monitor mood in combination with the capture of
phone sensor data have already revealed promising ﬁndings.
Grunerbl et al. (2015) recruited ten participants who were fol-
lowed for 12 weeks using smartphone-based sensor modalities.
They processed social interaction, physical motion, speech, and
travel pattern data to detect depressive and manic states. Mood
ratings were performed by clinicians on a three weekly basis. Gi-
ven the predominance of mood instability in bipolar disorder and
the burden of frequent clinician assessment MZ may provide a
critical link between objective sensor-derived data and mood. Si-
milarly, there is increasing interest in the use of other sensors and
additional data modalities (Lanata et al., 2015; Valenza et al.,
2013).
5.1. The validity of MZ smart phone measures
In principle, participants could complete MZ on paper instead
of a smartphone. However, there are numerous advantages to
using a smartphone to collect mood data: (a) the smartphone
prompts participants for completing the questionnaire, hence
potentially increasing adherence, (b) the prompted response is
time-stamped, so that MZ completion beyond a time window
could be disregarded or processed differently, (c) alleviates the
common problem of deferred completion in paper-based ques-
tionnaires, (d) the participants do not need to carry papers for
mood self-assessment since everything is conveniently done on a
smartphone, (e) convenience in data storage and processing,
(f) the use of a smartphone opens up possibilities to record addi-
tional objective data which might be useful in mood monitoring,
e.g. phone use, activity, and GPS, to complement the self-reported
measures. Although it is difﬁcult to quantify the increase in ad-
herence as a result of using MZ as part of a smartphone application
compared to a paper-based form, participant feedback suggests
the reminder prompt in the MZ smartphone application increased
completion rates. This is in agreement with reports in other clin-
ical studies that adherence is improved as a result of using re-
minders (Fenerty et al., 2012; Vervloet et al., 2012).
The validity of the daily MZ measures of emotion was con-
ﬁrmed by their correlationwith standard scales. There is no widely
used mood monitoring questionnaire used on a daily basis against
which to compare MZ. The standard mood questionnaires used in
this study (ASRM, QIDS, GAD-7, EQ-5D) could have been, in prin-
ciple, used on a daily basis, but they include a large number of
items collectively and are comprised of lengthy questions which
would be cumbersome and time-consuming to be completed daily.
On the other hand, the new compact MZ questionnaire, which ﬁts
on the smartphone's screen and takes a couple of seconds to be
completed, can be effectively used on a long-term daily basis. The
validation of the daily MZ against the weekly questionnaires re-
quires summarizing the seven MZ entries on a single value to be
compared against each the weekly entries in the TC ques-
tionnaires. To this end, we associated the average of the seven MZ
entries with TC in Table 3, and further explored alternative ap-
proaches to associate MZ and TC in the Supplementary material
using: (a) the median MZ scores (S6), (b) only the last three days of
MZ entries preceding the TC record (S7), and (c) the MZ entries on
the same day that TC was recorded (S8). In fact, the report of
weekly symptoms may be primarily related to symptoms on the
day of the assessment rather than a true average of the preceding
week (compare Table 3 and Table S8 in the Supplementary ma-
terial). This observation, if correct, further supports the need to usehigher frequency monitoring to quantify mood instability, and
casts doubt on the usual assumption that weekly questionnaires
encapsulates experience over the preceding week.
We also determined the latent variable MZ structure as two
principal components: negative affect, and positive affect, which
together accounted for almost 80% of the variance. This ﬁnding
strongly conﬁrms many studies of normal emotion in psychology,
where negative and positive affects are not simply inversely pro-
portional (Anastasi, 1982). To the best of our knowledge, this
ﬁnding has not been described in such detail in BD and BPD pa-
tient groups before. In these groups, the principal component
capturing negative emotion was larger than that capturing positive
emotion and vice versa in HC (Supplementary Tables S1, S2, and
S3), because depressed mood was more prevalent.
The negative principal component of MZ was statistically very
strongly associated with depression, anxiety, and quality of life
scores. All nine QIDS domains showed similar association strength
(0.4–0.7), strongly associated with the four negative MZ items
(anxious, sad, angry, and irritable). In conclusion, our ﬁndings
strongly support the use of MZ to capture negative mood in pa-
tients with abnormal mood and healthy volunteers.
The positive principal component of MZ was weakly correlated
with scores of manic symptoms with ASRM. It is slightly surprising
that ASRM items to capture happiness and activity were not more
congruent with MZ scores for elation and energy. It is not obvious
which is preferable. Relatively few manic symptoms (as measured
by the ARSM) were reported during the study and there may be a
general difﬁculty with capturing elated mood using self-reported
assessment, as reported in previous studies (Faurholt-Jepsen et al.,
2015).
We tentatively interpreted the third MZ principal component
as “irritability”, but it is not stable when analysing the data within
the three groups (see Tables S1, S2, S3). Nonetheless, this MZ
component appears to differentiate the three groups (see Table 4);
in particular BD and BPD can be distinguished better using irrit-
ability MZ than positive MZ. The results in Table 5 suggest that the
ﬁrst principal component of MZ is statistically very strongly as-
sociated with depression, anxiety, and quality of life scores, whilst
the other principal components exhibit considerably weaker
associations.
5.2. Differences between patients and controls
Although BD has been traditionally considered to be dominated
by mania and depression, anxiety is a common comorbid factor
(Simon et al., 2004). The ﬁndings in this study strongly support the
argument for measuring anxiety as part of the diagnostic and
monitoring protocol. The variability in the questionnaires was
quantiﬁed using relatively straightforward statistical descriptors
and algorithms, where TKEO and RMSSD lead to satisfactory dif-
ferentiation of the three groups (see Table 5). Although it may be
difﬁcult to differentiate BD and BPD with the classical ques-
tionnaires in some cases, e.g. in terms of ASRM and GAD-7, MZ can
successfully distinguish the two cohorts (see Table 5), which is of
potential clinical importance (Saunders et al., 2015). This is the
ﬁrst study to demonstrate such a clear distinction between BD and
BPD on the basis of a simple quantiﬁcation of mood instability. It
also highlights that different disorders require different sampling
frequencies to optimally capture mood variability.
5.3. Overview of the different measures of variability
The variability of the longitudinal responses to the ques-
tionnaires can be quantiﬁed using time-series tools. The standard
deviation is the most well-known generic descriptor to quantify
variability, but may be limited in the presence of outliers or data
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of overall uncertainty, but is not sensitive to local ﬂuctuations and
relies on accurate estimation of the underlying density. RMSSD is a
standard approach summarizing the successive squared differ-
ences, but only captures information contained in the amplitude
changes. Finally, TKEO is a more sophisticated operator accounting
for both the amplitude and the frequency of the time-series
variability. These are general considerations, and in practice it is
useful to apply the different operators since there is no approach
which is universally best.
5.4. Limitations
Despite the promising ﬁndings reported in this study, there are
certain limitations. Most of the BD participants were recruited
from a larger study, and hence may have been more compliant
than a new cohort in this diagnostic group. Nevertheless, the vast
majority of participants stayed in the study beyond the originally
minimum period of 3 months, which suggests that participants
found the study engaging. Qualitative feedback from participants
suggested that they found the completion of regular mood ratings
helpful. This may have reduced the symptom burden they ex-
perienced and also have improved the recall of the weekly ratings.
We also remark that while the study cohort was representative of
a subgroup of psychiatric outpatients, it did not include those who
were psychotic or who had signiﬁcant comorbidities. This study
was observational in nature and we had very little contact with
participants; although we have recorded the pharmacological
treatment initially, we do not have accurate information on
changes in medication through the duration of the study. Given
that there is emerging evidence that mood instability is associated
with poor clinical outcomes in diverse mental disorders (Broome
et al., 2015; Patel et al., 2015), future studies could investigate
further potential differences amongst psychiatric groups. Another
direction would be investigating gender- and age-based effects on
mood instability, which would ideally require a larger and more
balanced dataset (in particular more male BPD). Finally, all the
reported scores rely on self-assessment; there is a lack of ongoing
clinical assessment by experts to validate the ﬁndings: as dis-
cussed above, self-reported measures on mania may not be re-
ﬂective of the true clinical condition (Faurholt-Jepsen et al., 2016).6. Conclusion
The ﬁndings in this study support the use of MZ for efﬁcient,
long-term, effective daily monitoring of mood instability in clinical
psychiatric practice. People diagnosed with BPD show higher rat-
ings of distress compared to BD (or HC). The increased amplitude
of ratings of negative mood and anxiety were accompanied by
greater day-to-day variability in the BPD group. Such measures of
mood instability may prove useful in measuring outcome in both
BD and BPD patients and as a target for measuring the efﬁcacy of
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